Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers K > Headlines for Keryx Biopharmaceuticals, Inc. > News item |
Keryx maintained by Jefferies at buy
Keryx Biopharmaceuticals Inc. was maintained by Jefferies & Co. analyst Adam Walsh at a buy rating with a price target on the stock of $20 per share following second-quarter results. Keryx shares Wednesday were down $0.21, or 1.23%, at $16.83 on volume of 423,204 shares versus the three-month running average of 512,594 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.